Details of Drug-Drug Interaction
| Drug General Information (ID: DDI3CJ8G9X) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Topiramate | Drug Info | Ethotoin | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Anticonvulsants | Anticonvulsants | |||||||
| Structure | |||||||||
| Mechanism of Topiramate-Ethotoin Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Decreased metabolism (Unspecific) Click to Show/Hide Mechanism Graph | |||||||||
| Drug Name | Topiramate | Ethotoin | |||||||
| Mechanism | Inhibit the hepatic metabolism of hydantoins | Hydantoins | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Pharmacokinetics | ||||||||
| Factor Description | Alters the metabolism of the drug, leading to changes in the plasma concentration of the drug and affecting the pharmacological effects. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Patients should be closely observed for clinical response and signs of hydantoin toxicity if these drugs must be given concurrently and serum concentrations should be monitored. Patients should be advised to notify their physician if they experience loss of seizure control or symptoms of hydantoin toxicity, including drowsiness, visual disturbances, change in mental status, seizures, nausea, or ataxia. Addition or withdrawal of hydantoins during therapy with topiramate may require a dose adjustment of topiramate and/or the hydantoin. | ||||||||